Dexcom Inc.

DXCM · Nasdaq · ·

Karşılaştır

$83,29+%2,313 Kas kapanış

30 Eylül 2026 tarihine kadarki rakamlar, 29 Ekim 2026 tarihinde sunulan 10-Q raporundan

1W: +%4,9
1M: -%0,2

Just reported

Q3 2026 results

From Dexcom's results release of 29 Ekim 2026; its quarterly report has since been filed.

Revenue
Actual
$1,34B
+%11 y/y
+%2,8 q/q
Guided
—
No guide given
EPS, GAAP
Actual
$0,72
+%2,9 y/y
+%13 q/q
Guided
—
No guide given
Operating income, GAAP
Actual
$327,2M
+%35 y/y
+%2,8 q/q
Guided
—
No guide given

Company outlook

Full year 2026

Revenue$5,2B – $5,25B+%12 y/y Unchanged

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

Keep exploring

The themes Dexcom is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

The theme it is part of

Seçki
Medical devices
InspectStocks tarafından · 20 companies
Surgical robots, implants, heart devices, glucose monitors and other medical equipment.
Fiyat, 1 yıl
+%6,2
Gelir, 1 yıl
+%7,2
+14
A 8B 7C 3D 2

Highest-graded in Medical Devices

Graded A or B and worth $2B or more: A first, then the largest.

All 133 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

Tüm finansal tablolar →

Dexcom Inc. şirketinin ABD Menkul Kıymetler ve Borsa Komisyonu’na (SEC) sunduğu kendi belgelerinden kuruldu. Rakamlar bildirildiği gibidir; hisse başına geçmiş bugünkü hisse tabanına göre yeniden hesaplanmıştır. Bu bir işletmeyi anlatır — yatırım tavsiyesi değildir ve alma ya da satma önerisi değildir.

Dexcom Inc.

Dexcom Inc.

Q3 2026 results

Revenue

EPS, GAAP